Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRP + PBD-VSEL is a combination therapy that utilizes platelet-rich plasma (PRP) and peripheral blood derived very small embryonic-like (PBD-VSEL) stem cells. The treatment involves first extracting a patient's blood, processing it to concentrate platelets and isolate VSEL stem cells, and then reinjecting this preparation into targeted areas of the body. The PRP component contains concentrated platelets with growth factors that promote healing and tissue regeneration. The VSEL stem cells are unique in that they can potentially differentiate into various cell types in the body. When combined, these components work synergistically to enhance healing, reduce inflammation, and potentially regenerate damaged tissues. This therapy is being investigated for various conditions, particularly neurological disorders like Parkinson's disease, where it may help repair damaged neural tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PRP + PBD-VSEL.